Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Discovery of a fusion kinase in EOL-1 cells and idiopathic hypereosinophilic syndrome

13 Jun 2003

Abstract excerpt

Idiopathic hypereosinophilic syndrome (HES) is a myeloproliferative disease of unknown etiology. Recently, it has been reported that imatinib mesylate (Gleevec), an inhibitor of Bcr-Abl kinase useful in the treatment of chronic myeloid leukemia, is also effective in treating HES; however, the molecular target of imatinib in HES is unknown. This report identifies a genetic rearrangement in the eosinophilic cell...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chronic Myeloid Leukemia Treatments
Share to Eosinophilic Disorders and Syndromes
Share to Myeloproliferative Neoplasms: Diagnosis and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 12808148
DOI: 10.1073/pnas.0932698100

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Discovery of a fusion kinase in EOL-1 cells and idiopathic hypereosinophilic syndromePMID 12808148Read ↗

The FIP1L1-PDGFRα fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and managementSemantic proximity Read ↗

The FIP1L1-PDGFR?? kinase in hypereosinophilic syndrome and chronic eosinophilic leukemiaSemantic proximity Read ↗

Imatinib for the treatment of hypereosinophilic syndromes.Semantic proximity Read ↗

FIP1L1-PDGFRalpha alone or with other genetic abnormalities reveals disease progression in chronic eosinophilic leukemia but good response to imatinib.Semantic proximity Read ↗

Imatinib therapy for hypereosinophilic syndrome and eosinophilia-associated myeloproliferative disorders.Semantic proximity Read ↗

Imatinib has limited therapeutic activity for hypereosinophilic syndrome patients with unknown or negative PDGFRalpha mutation status.Semantic proximity Read ↗

Molecular Classification and Pathogenesis of Eosinophilic Disorders: 2005 UpdateSemantic proximity Read ↗

The hypereosinophilic syndromes: current concepts and treatments.Semantic proximity Read ↗

Fibroblast Growth Factor Receptor and Platelet-Derived Growth Factor Receptor Abnormalities in Eosinophilic Myeloproliferative DisordersSemantic proximity Read ↗

Idiopathic Hypereosinophilic Syndrome in ChildrenSemantic proximity Read ↗

Identification of a novel imatinib responsive KIF5B-PDGFRA fusion gene following screening for PDGFRA overexpression in patients with hypereosinophiliaSemantic proximity Read ↗

Genomics of PDGFR-rearranged hypereosinophilic syndromeSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.